Special Issue "Humoral and Cellular Response after COVID-19 Vaccination"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 18036
COVID-19 vaccines are effective for infection outbreak control. However, waning immunity over time and the emergence of new SARS-CoV-2 variants have caused immune resistance to current vaccines.
This Special Issue focuses on the long-term humoral and cellular responses after COVID-19 vaccination.
We are interested in manuscripts that focus on emerging issues in COVID-19 vaccination immune response as well as factors influencing current vaccines’ effectiveness. Papers identifying novel strategies for improving immune response in immunocompromised patients are also of interest.
Since the long-term efficacy of COVID-19 vaccines is still unknown, we are calling for studies on both humoral and cellular long-term immunity as well as those investigating the immunity effectiveness of additional booster vaccine doses.
The submission of original articles, systematic reviews, and short communications on related topics are welcome.
Dr. Michal Herman-Edelstein
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- SARS-CoV-2 vaccines
- booster dose (second and third doses)
- T- and B-cell immune response
- humoral immune response
- neutralizing antibodies
- anti-SARS-CoV-2 spike antibodies